Global Vaccine Contract Manufacturing
Global Vaccine Contract Manufacturing

Vaccine Contract Manufacturing Comprehensive Study by Type (Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines), Application (Mammalian, Microbial, Others), Scale of Operation (Preclinical, Clinical, Commercial), Business Operations (Cell / Virus Banking, Analytical Testing, Formulation Development, Process Development, Fill / Finish, Packaging), End-Use (Pharmaceutical Companies, Biotech Companies, Others) Players and Region - Global Market Outlook to 2026

Vaccine Contract Manufacturing Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 232 Pages 194 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Vaccine Contract Manufacturing Market Scope
Contract pharma m manufacturing practices contain all methods that are essential to develop Pharma services. These practices provide minimum requirements that has to and will be met by pharmaceutical companies so as to supply high-quality products that may position no risk to the patients/consumers at large. The pharmaceutical contract manufacturing process includes Pharmaceutical machinery, drug manufacturers contracting a firm for finished products or components. It will be seen as a sort of outsourcing. Contract manufacturing helps drug manufacturers within the extensive drug discovery process by lightening a number of the costly burdens committed to data research, testing, project management, and drug trials that are run on a post-approval, pre-clinical and clinical basis.

The Vaccine Contract Manufacturing market study is segmented by Type (Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines and DNA Vaccines), by Application (Mammalian, Microbial and Others) and major geographies with country level break-up.

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Vaccine Contract Manufacturing market throughout the predicted period.

Diosynth (Netherlands), Emergent BioSolutions (United States), Goodwin Biotechnology (United States), Bavarian Nordic (Denmark), Soligenix Inc. (United States), Catalent Biologics (United States), Lonza (Switzerland), IDT Biologika (Germany) and Merck KGaA (Germany) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Vaccine Contract Manufacturing market by Type, Application and Region.

On the basis of geography, the market of Vaccine Contract Manufacturing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


According to Food and Drug Administration (FDA), each party engaged in the manufacture of a drug is responsible for ensuring compliance with Current Good Manufacturing Practice regulations (CGMP) for the manufacturing activities it performs. For both owners and contract facilities that conduct manufacturing operations, CGMP “includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.” The FD&C Act also prohibits any person from introducing or delivering for introduction an adulterated or misbranded drug into interstate commerce.

Market Trend
  • Rise in Demand of Generic Drugs and Complex Pharmaceutical Products
  • Emphasizing On Development of Cost-Effective Pharmaceuticals

Market Drivers
  • Increasing Geriatric Population and Prevalence of Chronic Diseases
  • Growing R&D Activities Led to Rise in Number of Pharmaceutical Products in the Pipeline

Opportunities
  • Growing Demand for Outsourcing Services for Healthcare from Developing Economies
  • Growing Biopharmaceutical Industry

Restraints
  • Huge Initial Investment for Vaccine Contract Manufacturing Services
  • Data Security and Privacy Concerns Associated with Vaccine Contract Manufacturing

Challenges
  • Lack of Advance Healthcare Facilities in Emerging Countries


Key Target Audience
Biotechnology and pharmaceutical companies, Government agencies, Contract Research Organization, Academic and Research Institutions, Hospitals and Diagnostic Centers, Market Research and Consulting Firms, Venture Capitalists and Investors and Others

Frequently asked questions:
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Vaccine Contract Manufacturing Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Type
  • Attenuated Vaccine
  • Inactivated Vaccine
  • Subunit Vaccines
  • Toxoid Vaccines
  • DNA Vaccines
By Application
  • Mammalian
  • Microbial
  • Others
By Scale of Operation
  • Preclinical
  • Clinical
  • Commercial

By Business Operations
  • Cell / Virus Banking
  • Analytical Testing
  • Formulation Development
  • Process Development
  • Fill / Finish
  • Packaging

By End-Use
  • Pharmaceutical Companies
  • Biotech Companies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population and Prevalence of Chronic Diseases
      • 3.2.2. Growing R&D Activities Led to Rise in Number of Pharmaceutical Products in the Pipeline
    • 3.3. Market Challenges
      • 3.3.1. Lack of Advance Healthcare Facilities in Emerging Countries
    • 3.4. Market Trends
      • 3.4.1. Rise in Demand of Generic Drugs and Complex Pharmaceutical Products
      • 3.4.2. Emphasizing On Development of Cost-Effective Pharmaceuticals
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Vaccine Contract Manufacturing, by Type, Application, Scale of Operation, Business Operations, End-Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Vaccine Contract Manufacturing (Value)
      • 5.2.1. Global Vaccine Contract Manufacturing by: Type (Value)
        • 5.2.1.1. Attenuated Vaccine
        • 5.2.1.2. Inactivated Vaccine
        • 5.2.1.3. Subunit Vaccines
        • 5.2.1.4. Toxoid Vaccines
        • 5.2.1.5. DNA Vaccines
      • 5.2.2. Global Vaccine Contract Manufacturing by: Application (Value)
        • 5.2.2.1. Mammalian
        • 5.2.2.2. Microbial
        • 5.2.2.3. Others
      • 5.2.3. Global Vaccine Contract Manufacturing by: Scale of Operation (Value)
        • 5.2.3.1. Preclinical
        • 5.2.3.2. Clinical
        • 5.2.3.3. Commercial
      • 5.2.4. Global Vaccine Contract Manufacturing by: Business Operations (Value)
        • 5.2.4.1. Cell / Virus Banking
        • 5.2.4.2. Analytical Testing
        • 5.2.4.3. Formulation Development
        • 5.2.4.4. Process Development
        • 5.2.4.5. Fill / Finish
        • 5.2.4.6. Packaging
      • 5.2.5. Global Vaccine Contract Manufacturing by: End-Use (Value)
        • 5.2.5.1. Pharmaceutical Companies
        • 5.2.5.2. Biotech Companies
        • 5.2.5.3. Others
      • 5.2.6. Global Vaccine Contract Manufacturing Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Vaccine Contract Manufacturing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Diosynth (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Emergent BioSolutions (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Goodwin Biotechnology (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bavarian Nordic (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Soligenix Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Catalent Biologics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lonza (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. IDT Biologika (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck KGaA (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Vaccine Contract Manufacturing Sale, by Type, Application, Scale of Operation, Business Operations, End-Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Vaccine Contract Manufacturing (Value)
      • 7.2.1. Global Vaccine Contract Manufacturing by: Type (Value)
        • 7.2.1.1. Attenuated Vaccine
        • 7.2.1.2. Inactivated Vaccine
        • 7.2.1.3. Subunit Vaccines
        • 7.2.1.4. Toxoid Vaccines
        • 7.2.1.5. DNA Vaccines
      • 7.2.2. Global Vaccine Contract Manufacturing by: Application (Value)
        • 7.2.2.1. Mammalian
        • 7.2.2.2. Microbial
        • 7.2.2.3. Others
      • 7.2.3. Global Vaccine Contract Manufacturing by: Scale of Operation (Value)
        • 7.2.3.1. Preclinical
        • 7.2.3.2. Clinical
        • 7.2.3.3. Commercial
      • 7.2.4. Global Vaccine Contract Manufacturing by: Business Operations (Value)
        • 7.2.4.1. Cell / Virus Banking
        • 7.2.4.2. Analytical Testing
        • 7.2.4.3. Formulation Development
        • 7.2.4.4. Process Development
        • 7.2.4.5. Fill / Finish
        • 7.2.4.6. Packaging
      • 7.2.5. Global Vaccine Contract Manufacturing by: End-Use (Value)
        • 7.2.5.1. Pharmaceutical Companies
        • 7.2.5.2. Biotech Companies
        • 7.2.5.3. Others
      • 7.2.6. Global Vaccine Contract Manufacturing Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Vaccine Contract Manufacturing: by Type(USD Million)
  • Table 2. Vaccine Contract Manufacturing Attenuated Vaccine , by Region USD Million (2015-2020)
  • Table 3. Vaccine Contract Manufacturing Inactivated Vaccine , by Region USD Million (2015-2020)
  • Table 4. Vaccine Contract Manufacturing Subunit Vaccines , by Region USD Million (2015-2020)
  • Table 5. Vaccine Contract Manufacturing Toxoid Vaccines , by Region USD Million (2015-2020)
  • Table 6. Vaccine Contract Manufacturing DNA Vaccines , by Region USD Million (2015-2020)
  • Table 7. Vaccine Contract Manufacturing: by Application(USD Million)
  • Table 8. Vaccine Contract Manufacturing Mammalian , by Region USD Million (2015-2020)
  • Table 9. Vaccine Contract Manufacturing Microbial , by Region USD Million (2015-2020)
  • Table 10. Vaccine Contract Manufacturing Others , by Region USD Million (2015-2020)
  • Table 11. Vaccine Contract Manufacturing: by Scale of Operation(USD Million)
  • Table 12. Vaccine Contract Manufacturing Preclinical , by Region USD Million (2015-2020)
  • Table 13. Vaccine Contract Manufacturing Clinical , by Region USD Million (2015-2020)
  • Table 14. Vaccine Contract Manufacturing Commercial , by Region USD Million (2015-2020)
  • Table 15. Vaccine Contract Manufacturing: by Business Operations(USD Million)
  • Table 16. Vaccine Contract Manufacturing Cell / Virus Banking , by Region USD Million (2015-2020)
  • Table 17. Vaccine Contract Manufacturing Analytical Testing , by Region USD Million (2015-2020)
  • Table 18. Vaccine Contract Manufacturing Formulation Development , by Region USD Million (2015-2020)
  • Table 19. Vaccine Contract Manufacturing Process Development , by Region USD Million (2015-2020)
  • Table 20. Vaccine Contract Manufacturing Fill / Finish , by Region USD Million (2015-2020)
  • Table 21. Vaccine Contract Manufacturing Packaging , by Region USD Million (2015-2020)
  • Table 22. Vaccine Contract Manufacturing: by End-Use(USD Million)
  • Table 23. Vaccine Contract Manufacturing Pharmaceutical Companies , by Region USD Million (2015-2020)
  • Table 24. Vaccine Contract Manufacturing Biotech Companies , by Region USD Million (2015-2020)
  • Table 25. Vaccine Contract Manufacturing Others , by Region USD Million (2015-2020)
  • Table 26. South America Vaccine Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 27. South America Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 28. South America Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 29. South America Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 30. South America Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 31. South America Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 32. Brazil Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 33. Brazil Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 34. Brazil Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 35. Brazil Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 36. Brazil Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 37. Argentina Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 38. Argentina Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 39. Argentina Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 40. Argentina Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 41. Argentina Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 42. Rest of South America Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 43. Rest of South America Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 44. Rest of South America Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 45. Rest of South America Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 46. Rest of South America Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 47. Asia Pacific Vaccine Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 48. Asia Pacific Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 49. Asia Pacific Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 50. Asia Pacific Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 51. Asia Pacific Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 52. Asia Pacific Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 53. China Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 54. China Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 55. China Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 56. China Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 57. China Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 58. Japan Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 59. Japan Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 60. Japan Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 61. Japan Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 62. Japan Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 63. India Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 64. India Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 65. India Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 66. India Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 67. India Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 68. South Korea Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 69. South Korea Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 70. South Korea Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 71. South Korea Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 72. South Korea Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 73. Taiwan Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 74. Taiwan Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 75. Taiwan Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 76. Taiwan Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 77. Taiwan Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 78. Australia Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 79. Australia Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 80. Australia Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 81. Australia Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 82. Australia Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 86. Rest of Asia-Pacific Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 87. Rest of Asia-Pacific Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 88. Europe Vaccine Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 89. Europe Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 90. Europe Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 91. Europe Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 92. Europe Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 93. Europe Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 94. Germany Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 95. Germany Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 96. Germany Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 97. Germany Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 98. Germany Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 99. France Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 100. France Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 101. France Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 102. France Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 103. France Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 104. Italy Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 105. Italy Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 106. Italy Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 107. Italy Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 108. Italy Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 109. United Kingdom Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 110. United Kingdom Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 111. United Kingdom Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 112. United Kingdom Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 113. United Kingdom Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 114. Netherlands Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 115. Netherlands Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 116. Netherlands Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 117. Netherlands Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 118. Netherlands Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 119. Rest of Europe Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 120. Rest of Europe Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 121. Rest of Europe Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 122. Rest of Europe Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 123. Rest of Europe Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 124. MEA Vaccine Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 125. MEA Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 126. MEA Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 127. MEA Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 128. MEA Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 129. MEA Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 130. Middle East Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 131. Middle East Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 132. Middle East Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 133. Middle East Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 134. Middle East Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 135. Africa Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 136. Africa Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 137. Africa Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 138. Africa Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 139. Africa Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 140. North America Vaccine Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 141. North America Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 142. North America Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 143. North America Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 144. North America Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 145. North America Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 146. United States Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 147. United States Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 148. United States Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 149. United States Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 150. United States Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 151. Canada Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 152. Canada Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 153. Canada Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 154. Canada Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 155. Canada Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 156. Mexico Vaccine Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 157. Mexico Vaccine Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 158. Mexico Vaccine Contract Manufacturing, by Scale of Operation USD Million (2015-2020)
  • Table 159. Mexico Vaccine Contract Manufacturing, by Business Operations USD Million (2015-2020)
  • Table 160. Mexico Vaccine Contract Manufacturing, by End-Use USD Million (2015-2020)
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Vaccine Contract Manufacturing: by Type(USD Million)
  • Table 171. Vaccine Contract Manufacturing Attenuated Vaccine , by Region USD Million (2021-2026)
  • Table 172. Vaccine Contract Manufacturing Inactivated Vaccine , by Region USD Million (2021-2026)
  • Table 173. Vaccine Contract Manufacturing Subunit Vaccines , by Region USD Million (2021-2026)
  • Table 174. Vaccine Contract Manufacturing Toxoid Vaccines , by Region USD Million (2021-2026)
  • Table 175. Vaccine Contract Manufacturing DNA Vaccines , by Region USD Million (2021-2026)
  • Table 176. Vaccine Contract Manufacturing: by Application(USD Million)
  • Table 177. Vaccine Contract Manufacturing Mammalian , by Region USD Million (2021-2026)
  • Table 178. Vaccine Contract Manufacturing Microbial , by Region USD Million (2021-2026)
  • Table 179. Vaccine Contract Manufacturing Others , by Region USD Million (2021-2026)
  • Table 180. Vaccine Contract Manufacturing: by Scale of Operation(USD Million)
  • Table 181. Vaccine Contract Manufacturing Preclinical , by Region USD Million (2021-2026)
  • Table 182. Vaccine Contract Manufacturing Clinical , by Region USD Million (2021-2026)
  • Table 183. Vaccine Contract Manufacturing Commercial , by Region USD Million (2021-2026)
  • Table 184. Vaccine Contract Manufacturing: by Business Operations(USD Million)
  • Table 185. Vaccine Contract Manufacturing Cell / Virus Banking , by Region USD Million (2021-2026)
  • Table 186. Vaccine Contract Manufacturing Analytical Testing , by Region USD Million (2021-2026)
  • Table 187. Vaccine Contract Manufacturing Formulation Development , by Region USD Million (2021-2026)
  • Table 188. Vaccine Contract Manufacturing Process Development , by Region USD Million (2021-2026)
  • Table 189. Vaccine Contract Manufacturing Fill / Finish , by Region USD Million (2021-2026)
  • Table 190. Vaccine Contract Manufacturing Packaging , by Region USD Million (2021-2026)
  • Table 191. Vaccine Contract Manufacturing: by End-Use(USD Million)
  • Table 192. Vaccine Contract Manufacturing Pharmaceutical Companies , by Region USD Million (2021-2026)
  • Table 193. Vaccine Contract Manufacturing Biotech Companies , by Region USD Million (2021-2026)
  • Table 194. Vaccine Contract Manufacturing Others , by Region USD Million (2021-2026)
  • Table 195. South America Vaccine Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 196. South America Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 197. South America Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 198. South America Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 199. South America Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 200. South America Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 201. Brazil Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 202. Brazil Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 203. Brazil Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 204. Brazil Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 205. Brazil Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 206. Argentina Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 207. Argentina Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 208. Argentina Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 209. Argentina Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 210. Argentina Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 211. Rest of South America Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 212. Rest of South America Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 213. Rest of South America Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 214. Rest of South America Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 215. Rest of South America Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 216. Asia Pacific Vaccine Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 217. Asia Pacific Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 218. Asia Pacific Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 219. Asia Pacific Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 220. Asia Pacific Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 221. Asia Pacific Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 222. China Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 223. China Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 224. China Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 225. China Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 226. China Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 227. Japan Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 228. Japan Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 229. Japan Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 230. Japan Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 231. Japan Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 232. India Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 233. India Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 234. India Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 235. India Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 236. India Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 237. South Korea Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 238. South Korea Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 239. South Korea Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 240. South Korea Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 241. South Korea Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 242. Taiwan Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 243. Taiwan Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 244. Taiwan Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 245. Taiwan Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 246. Taiwan Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 247. Australia Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 248. Australia Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 249. Australia Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 250. Australia Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 251. Australia Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 252. Rest of Asia-Pacific Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 253. Rest of Asia-Pacific Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 254. Rest of Asia-Pacific Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 255. Rest of Asia-Pacific Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 256. Rest of Asia-Pacific Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 257. Europe Vaccine Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 258. Europe Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 259. Europe Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 260. Europe Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 261. Europe Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 262. Europe Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 263. Germany Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 264. Germany Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 265. Germany Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 266. Germany Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 267. Germany Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 268. France Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 269. France Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 270. France Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 271. France Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 272. France Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 273. Italy Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 274. Italy Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 275. Italy Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 276. Italy Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 277. Italy Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 278. United Kingdom Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 279. United Kingdom Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 280. United Kingdom Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 281. United Kingdom Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 282. United Kingdom Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 283. Netherlands Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 284. Netherlands Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 285. Netherlands Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 286. Netherlands Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 287. Netherlands Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 288. Rest of Europe Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 289. Rest of Europe Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 290. Rest of Europe Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 291. Rest of Europe Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 292. Rest of Europe Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 293. MEA Vaccine Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 294. MEA Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 295. MEA Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 296. MEA Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 297. MEA Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 298. MEA Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 299. Middle East Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 300. Middle East Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 301. Middle East Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 302. Middle East Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 303. Middle East Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 304. Africa Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 305. Africa Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 306. Africa Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 307. Africa Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 308. Africa Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 309. North America Vaccine Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 310. North America Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 311. North America Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 312. North America Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 313. North America Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 314. North America Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 315. United States Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 316. United States Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 317. United States Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 318. United States Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 319. United States Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 320. Canada Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 321. Canada Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 322. Canada Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 323. Canada Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 324. Canada Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 325. Mexico Vaccine Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 326. Mexico Vaccine Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 327. Mexico Vaccine Contract Manufacturing, by Scale of Operation USD Million (2021-2026)
  • Table 328. Mexico Vaccine Contract Manufacturing, by Business Operations USD Million (2021-2026)
  • Table 329. Mexico Vaccine Contract Manufacturing, by End-Use USD Million (2021-2026)
  • Table 330. Research Programs/Design for This Report
  • Table 331. Key Data Information from Secondary Sources
  • Table 332. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Vaccine Contract Manufacturing: by Type USD Million (2015-2020)
  • Figure 5. Global Vaccine Contract Manufacturing: by Application USD Million (2015-2020)
  • Figure 6. Global Vaccine Contract Manufacturing: by Scale of Operation USD Million (2015-2020)
  • Figure 7. Global Vaccine Contract Manufacturing: by Business Operations USD Million (2015-2020)
  • Figure 8. Global Vaccine Contract Manufacturing: by End-Use USD Million (2015-2020)
  • Figure 9. South America Vaccine Contract Manufacturing Share (%), by Country
  • Figure 10. Asia Pacific Vaccine Contract Manufacturing Share (%), by Country
  • Figure 11. Europe Vaccine Contract Manufacturing Share (%), by Country
  • Figure 12. MEA Vaccine Contract Manufacturing Share (%), by Country
  • Figure 13. North America Vaccine Contract Manufacturing Share (%), by Country
  • Figure 14. Global Vaccine Contract Manufacturing share by Players 2020 (%)
  • Figure 15. Global Vaccine Contract Manufacturing share by Players (Top 3) 2020(%)
  • Figure 16. Global Vaccine Contract Manufacturing share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Diosynth (Netherlands) Revenue, Net Income and Gross profit
  • Figure 19. Diosynth (Netherlands) Revenue: by Geography 2020
  • Figure 20. Emergent BioSolutions (United States) Revenue, Net Income and Gross profit
  • Figure 21. Emergent BioSolutions (United States) Revenue: by Geography 2020
  • Figure 22. Goodwin Biotechnology (United States) Revenue, Net Income and Gross profit
  • Figure 23. Goodwin Biotechnology (United States) Revenue: by Geography 2020
  • Figure 24. Bavarian Nordic (Denmark) Revenue, Net Income and Gross profit
  • Figure 25. Bavarian Nordic (Denmark) Revenue: by Geography 2020
  • Figure 26. Soligenix Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Soligenix Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Catalent Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Catalent Biologics (United States) Revenue: by Geography 2020
  • Figure 30. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Lonza (Switzerland) Revenue: by Geography 2020
  • Figure 32. IDT Biologika (Germany) Revenue, Net Income and Gross profit
  • Figure 33. IDT Biologika (Germany) Revenue: by Geography 2020
  • Figure 34. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 36. Global Vaccine Contract Manufacturing: by Type USD Million (2021-2026)
  • Figure 37. Global Vaccine Contract Manufacturing: by Application USD Million (2021-2026)
  • Figure 38. Global Vaccine Contract Manufacturing: by Scale of Operation USD Million (2021-2026)
  • Figure 39. Global Vaccine Contract Manufacturing: by Business Operations USD Million (2021-2026)
  • Figure 40. Global Vaccine Contract Manufacturing: by End-Use USD Million (2021-2026)
  • Figure 41. South America Vaccine Contract Manufacturing Share (%), by Country
  • Figure 42. Asia Pacific Vaccine Contract Manufacturing Share (%), by Country
  • Figure 43. Europe Vaccine Contract Manufacturing Share (%), by Country
  • Figure 44. MEA Vaccine Contract Manufacturing Share (%), by Country
  • Figure 45. North America Vaccine Contract Manufacturing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Diosynth (Netherlands)
  • Emergent BioSolutions (United States)
  • Goodwin Biotechnology (United States)
  • Bavarian Nordic (Denmark)
  • Soligenix Inc. (United States)
  • Catalent Biologics (United States)
  • Lonza (Switzerland)
  • IDT Biologika (Germany)
  • Merck KGaA (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation